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Abstract
Background: Mucosal human papillomavirus (HPV) infection is a necessary cause of cervical cancer. Vaccine and
non-vaccine genotype prevalences may change after vaccine introduction. Therefore, it appears essential to rank
HPV genotypes according to their oncogenic potential for invasive cervical cancer, independently of their respective
prevalences.
Methods: We performed meta-analyses of published observational studies and estimated pooled odds ratios with
random-effects models for 32 HPV genotypes, using HPV-16 as the reference.
Results: Twenty-seven studies yielded 9,252 HPV-infected women: 2,902 diagnosed with invasive cervical cancer
and 6,350 with normal cytology. Expressed as (odds ratio [95% confidence interval]), HPV-18 (0.63 [0.51, 0.78])
ranked closest to HPV-16, while other genotypes showed continuously decreasing relative oncogenic potentials:
HPV-45 (0.35 [0.22, 0.55]), HPV-69 (0.28 [0.09, 0.92]), HPV-58 (0.24 [0.15, 0.38]), HPV-31 (0.22 [0.14, 0.35]), HPV-33 (0.22
[0.12, 0.38]), HPV-34 (0.21 [0.06, 0.80]), HPV-67 (0.21 [0.06, 0.67]), HPV-39 (0.17 [0.09, 0.30]), HPV-59 (0.17 [0.09, 0.31]),
HPV-73 (0.16 [0.06, 0.41]), and HPV-52 (0.16 [0.11, 0.23]).
Conclusions: Our results support the markedly higher oncogenic potentials of HPV-16 and -18, followed by
HPV-31, -33, -39, -45, -52, -58 and -59, and highlight the need for further investigation of HPV-34, -67, -69 and -73.
Overall, these findings could have important implications for the prevention of cervical cancer.
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Background
Invasive cervical cancer (ICC) is the third most common
cancer among women worldwide, with an estimated in-
cidence of 553,119 new cases and 288,109 deaths in
2010 [1]. Persistent infection with one of the oncogenic
human papillomavirus (HPV) genotypes is required to
cause ICC [2-5]. More than 150 HPV genotypes have
been identified and about 40 are known to infect the
genital tract [6,7].
To date, HPV genotypes identified as causing ICC have
belonged to a few genetically related “high-risk” species of
the mucosotropic α-genus (α-5, -6, -7, -9 and -11) [8] but
other HPV genotypes could be involved [9]. Dichotomous
classification into low- and high-risk HPV genotypes has
often been used previously [4,10]. Alternatively, the Inter-
national Agency for Research on Cancer (IARC) classified
individual HPV genotypes into more categories based on
available epidemiologic and mechanistic evidence of their
carcinogenicity for cancer at any site. Thus, 12 HPV
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genotypes (HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56,
-58 and -59) are classified as “carcinogenic to humans”
(Group 1), HPV-68 as “probably carcinogenic” (Group
2A) and 12 other HPV genotypes as “possibly carcino-
genic” (Group 2B) [8,11].
Two vaccines targeting HPV-16 and -18, which account
for 70% of cervical cancers worldwide [12,13], are cur-
rently available. Vaccination impact on the cervical cancer
incidence remains uncertain, especially because genotype-
specific prevalences of vaccine and non-vaccine geno-
types might change after vaccine introduction through
vaccine-induced cross-protection or genotype replace-
ment [14-16]. The number of ICC cases associated with
a given HPV genotype depends both on its prevalence
in the general population and its oncogenic potential,
which can be defined as the inherent and differential
abilities of each genotype to trigger malignant trans-
formation and induce cervical cancer [17]. Within cat-
egories of IARC-classified carcinogenic HPV genotypes,
the risk of progression to ICC might differ by HPV
genotype. Therefore, ranking the oncogenic potentials
of HPV genotypes, independently of their respective
prevalences, is challenging but essential to guide the
formulation of second-generation polyvalent HPV vac-
cines and HPV-DNA–based screening tests.
This study was undertaken to rank HPV genotypes as
causal agents of ICC according to their relative onco-
genic potentials assessed by means of meta-analyses of
published observational data. Oncogenic potentials
herein are expressed using HPV-16 as the reference,
since it has been recognized as the most carcinogenic
HPV genotype [8,11,18].
Methods
Literature search and study selection
Original studies published in English, French, German and
Spanish from 1/1995 to 3/2011 were systematically sought
in PubMed/Medline and Embase databases, in March
2011. The following keywords were combined: “female”,
“papillomavirus infection”, “DNA probes, HPV”, “DNA,
viral”, “genotype”, “polymerase chain reaction”, “sequence
analysis, DNA”, “uterine cervical neoplasms”, “cervix
uteri”, “epidemiologic studies”, “prevalence”, “incidence”
(Additional file 1). We restricted our selection to original
articles (reviews, meta-analyses, editorials, comments and
letters were not eligible). Conference abstracts and other
unpublished articles were not considered.
First, article titles and abstracts were screened then full
texts were read to check inclusion criteria. The relevance
of references cited in the retrieved articles, reviews and
meta-analyses was also evaluated for potential inclusions.
When necessary, authors were contacted for confirmation
of inclusion criteria or results.
Unvaccinated women of any age were considered for
this meta-analysis. We defined the following three in-
clusion criteria: prevalence data for at least one HPV
genotype other than HPV-16 and -18; inclusion of ≥20
HPV-infected women with ICC and ≥20 HPV-infected
women with normal cytology, and HPV-prevalence data
for women with ICC presented separately from those
with normal cytology.
One author (EB) conducted the eligibility assessment
and problematic papers were resolved by collegial
discussion (MPS, ACMT). BibDesk 1.5.4 software was
used to manage references.
Data extraction
For each study, one author (EB) extracted the following
data, entering them into a predefined Excel spreadsheet:
study characteristics (first author, year of publication,
journal, country and continent, design and funding
source), characteristics of included subjects (number of
cases [total and by histologic type, if available] and con-
trols, age data), methods (cytologic or histologic cervical
specimen, identification and typing method, primers
used [if any] and number of HPV genotypes detectable)
and results (numbers of HPV genotypes actually identified,
and simple and multiple infections, genotype-specific
HPV-prevalence data for cases and controls). For multiple
infections with ≥2 HPV genotypes, no weighting was used
and each HPV genotype was counted equally. Infection
with an uncharacterized HPV genotype is denoted HPV-X.
Furthermore, study quality was assessed with a list of
specifically defined criteria, inspired by some of the
STROBE checklist items [19]. The following items were
coded yes, no, unclear or missing: comparability of cases
and controls for geographic origin, age, sample type and
methods used to detect and genotype HPV; blinded
assessment; numbers of individuals reported at each
study stage; and genotype prevalences reported for
multiple infections. Data extraction was double checked
by two authors (MPS, ACMT).
Statistical analyses
A meta-analysis was performed for each HPV genotype,
after excluding studies that did not seek or report the
genotype under consideration and those that sought it
but reported zero cases and controls. Therefore, the
number of studies analyzed varied from one genotype to
another. We did not consider genotypes for which all
but one study reported zero controls. For each study
and each available genotype, an odds ratio (OR) and its
95% confidence interval (CI) were computed from the
reported numbers of case and control infections, consider-
ing HPV-16 infections as the reference group. Then, each
HPV genotype was subjected to meta-analysis across the
corresponding number of studies by combining the
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studies’ ORs using DerSimonian and Laird’s random-
effects model [20]. If a count equalled zero when cross-
tabulating case–control status and infection with a
given HPV genotype or HPV-16 (usually no controls
infected with the HPV genotype under consideration),
we applied a continuity correction (CC) by adding 0.5
to each cell [21,22].
For each HPV genotype, heterogeneity of the estimated
oncogenic potentials relative to HPV-16 was assessed
graphically with forest plots, and quantitatively using
Cochran’s Q-test and the I2 statistic [23,24]. When
Cochran’s Q-test was statistically significant at the 10%
level or the I2 statistic ≥50%, we examined potential
sources of heterogeneity by performing subgroup ana-
lyses according to five prespecified factors: study design
(case–control versus cross-sectional), year of publication
(before and after the median, ≤2005 versus >2005),
comparability of case and control ages (similar versus
unbalanced distribution or unclear information), geo-
graphic area (Asia [18,25] versus all other continents),
and HPV-detection level among cases (<90% versus ≥90%
threshold). For each HPV genotype, we assessed publi-
cation bias (or other potential sources of bias) by exam-
ining the funnel plots for asymmetry and running the
Egger test [26].
Sensitivity analyses were performed using: a fixed-effect
model, with Peto’s method [27], CC = 0.25 or 0, and HPV-
negative subjects as the reference group.
All statistical analyses were computed using the package
Meta-analysis in Stata in Stata/SE v11.0 [28,29].
Results
Study identification and description
The Medline and Embase database searches provided,
respectively, 757 and 182 references, while additional
searches identified 11 studies, yielding, after deleting 55
duplicates, a total of 895 references (Figure 1). Among
them, 794 were excluded based on their titles and ab-
stracts. The full texts of the remaining 101 references were
read and 27 studies fully satisfying the inclusion criteria
were finally retained [30-56]: 17 case–control and 10
cross-sectional studies, published between 1997 and 2011,
all but one (Spanish [30]) written in English. They had
been conducted on four continents: Asia (12 studies),
Europe (six studies), South and Central America (five
studies), and Africa (four studies). A total of 3,191 women
with ICC (cases) and 29,623 with normal cytology
(controls) were included (Table 1).
When available, mean age ranges were 44–56 years for
cases and 32–52 years for controls. Case and control
ages were comparable in five studies but not in eight
others, and this information was unclear or missing in
the 14 other papers. The cervical specimens used to de-
tect HPV infection were usually cytologic for controls
(23 studies) and histologic for cases (13 studies), with
specimen type being similar for cases and controls in 14
studies. All studies used polymerase chain reaction
(PCR) to detect HPV infection and 4–48 HPV genotypes
could be identified in each study (4–20 in cases, 4–36 in
controls). HPV infection was detected in 73–100% of
cases (squamous cell carcinoma: 80–100%; adenocarcin-
oma: 50–100%) and 5–76% of controls (except in [33]
which included only 24 controls, all HPV-positive).
Estimation of the genotype-specific oncogenic potential
compared to HPV-16
In total, 9,252 HPV-infected women (2,902 cases and
6,350 controls) were included (Table 1). Among HPV-
positive subjects, multiple infections were more frequent
in women with normal cytology (16% on average and up
to 50%) than those diagnosed with ICC (10% on average
and up to 35%). A total of 3,150 HPV infections, including
Database literature searches
Limits: 1995–2011
Languages: English, German, Spanish, French
757 PubMed
182 Embase
895 Total search results
Article titles and abstracts screened
101 Eligible
Full-text reading and application of inclusion criteria
27  Studies retained
Additional literature searches
4 References cited in reviews 
and meta-analyses




Figure 1 Article identification and selection process for inclusion in the meta-analysis.
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multiple infections, were identified among the 2,902 cases.
The most common HPV genotypes identified in women
with ICC were, in descending order: HPV-16 (57.9%),
HPV-18 (12.8%), HPV-45 (4.8%), HPV-58 (4.7%), HPV-33
(4.7%), HPV-31 (4.4%) and HPV-52 (4.0%). Prevalences of
the other HPV genotypes were <4% (Table 2). The overall
HPV-X prevalence was 7.6% but this value represents dif-
ferent numbers of genotypes from one study to another.
Available data enabled assessment of the relative onco-
genic potentials of 32 HPV genotypes (Table 2). Each
meta-analysis included two (HPV-74) to 27 (HPV-18)
studies (forest plots in Additional file 2). All pooled ORs
were statistically significantly <1, except for HPV-74
(two-sided P = 0.20, calculated from two studies, one of
which provided only one case, Figure 2). HPV-18 had
the highest OR (0.63; 95% CI, [0.51, 0.78]); HPV-45 the
second highest (0.35 [0.22, 0.55]) followed closely by the
others, in descending order: HPV-69 (0.28 [0.09, 0.92]),
HPV-58 (0.24 [0.15, 0.38]), HPV-31 (0.22 [0.14, 0.35]),
HPV-33 (0.22 [0.12, 0.38]), HPV-34 (0.21 [0.06, 0.80]), HPV-
67 (0.21 [0.06, 0.67]), HPV-39 (0.17 [0.09, 0.30]), HPV-59
(0.17 [0.09, 0.31]), HPV-73 (0.16 [0.06, 0.41]), and HPV-52
(0.16 [0.11, 0.23]). The ORs for the remaining HPV
genotypes were <0.15.
Heterogeneity and bias assessment
Cochran’s Q-test suggested heterogeneity for six HPV
genotypes: HPV-31, -33, -45, -51, -58 and -74; and the I2
Table 1 Characteristics of studies, numbers of women with invasive cervical cancer (cases) or normal
cytology (controls)
First author, year [reference] Country Study design Cases, n Controls, n
HPV+ Total HPV+ Total
Abba, 2003 [30] Argentina Cross-sectional 21 21 70 152
Alibegashvili, 2011 [31] Georgia Case–control 91 91 143 1,247
An, 2003 [32] South Korea Cross-sectional 48 50 72 276
Andersson, 2005 [33] Sweden Cross-sectional 45 45 24 24
Asato, 2004 [34] Japan Case–control 311 356 333 3,249
Baay, 2001 [35] Belgium Case–control 101 115 31 286
Bardin, 2008 [36] Poland Case–control 87 88 115 799
Castellsagué, 2008 [37] Mozambique Case–control 230 241 148 195
Chang, 1997 [38] China Case–control 39 47 42 72
Chaouki, 1998 [39] Morocco Case–control 144 152 38 185
Cho, 2003 [40] South Korea Cross-sectional 43 49 132 414
Ferrera, 1999 [41] Honduras Case–control 83 104 170 438
Hammouda, 2011 [42] Algeria Case–control 167 171 39 732
Herrero, 2005 [43] Costa-Rica Cross-sectional 34 35 1,671 7,459
Hong, 2008 [44] China Case–control 172 181 91 217
Illades-Aguiar, 2009 [45] Mexico Case–control 133 133 91 256
Illades-Aguiar, 2010 [46] Mexico Cross-sectional 141 141 1,274 3,117
Keita, 2009 [47] Guinea Case–control 70 77 360 752
Lee, 2007 [48] South Korea Cross-sectional 133 160 388 1,650
Liu, 2010 [49] China Case–control 111 134 274 613
Maehama, 2005 [50] Japan Case–control 330 383 434 4,078
Park, 2004 [51] South Korea Cross-sectional 59 62 51 290
Sasagawa, 2001 [52] Japan Case–control 75 84 151 1,562
Sherpa, 2010 [53] Nepal Case–control 54 61 73 898
Tachezy, 1999 [54] Czech Republic Cross-sectional 36 49 38 165
Tornesello, 2006 [55] Italy Case–control 53 65 36 183
Wu, 2010 [56] China Cross-sectional 91 96 61 314
Total 2,902 3,191 6,350 29,623
HPV+, human papillomavirus-positive.
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statistic for four among them: HPV-31, -33, -58 and -74
(Table 2). This heterogeneity was not clearly explained
by any of the factors considered (study design, year of
publication, geographic area, age-distribution balance
between cases and controls, or HPV-detection rate
among cases). For example, the I2 statistic was smaller
for cross-sectional studies than case–control studies for
HPV-33, -51 and -58, but higher for HPV-31 and -45.
For HPV-74, subgroup analyses could not be completed
because too few studies were included.
Moreover, no evidence of publication bias was found. No
obvious asymmetry of the funnel plots was observed, ex-
cept for HPV-18, -31 and -35, with slightly more small
studies reporting higher ORs (Additional file 3). The Egger
test was borderline or statistically significant only for HPV-
6 (P = 0.091), HPV-35 (P = 0.040) and HPV-62 (P = 0.065).
Table 2 Human papillomavirus genotype-specific prevalences among invasive cervical cancer cases, meta-analytical
estimates of relative oncogenic potentials
HPV- Prevalence* Cases†, n Pooled OR 95% CI Studies‡, n Cochran’s
Q-test P
I2 statistic, % Between-study
variance
n (%)
6 17 (0.8) 2,208 0.08 0.04, 0.16 18 0.162 24.8 0.438
11 17 (1.1) 1,554 0.11 0.06, 0.19 15 0.407 4.1 0.049
16 1,680 (57.9) 2,902 Reference 27
18 372 (12.8) 2,902 0.63 0.51, 0.78 27 0.425 2.6 0.009
30 2 (0.5) 430 0.13 0.03, 0.60 3 0.881 0.0 0.000
31 122 (4.4) 2,745 0.22 0.14, 0.35 24 <0.001 55.9 0.696
33 128 (4.7) 2,728 0.22 0.12, 0.38 24 <0.001 65.1 1.152
34 1 (0.2) 666 0.21 0.06, 0.80 5 0.791 0.0 0.000
35 67 (2.7) 2,450 0.12 0.08, 0.17 21 0.408 4.0 0.032
39 24 (1.2) 2,017 0.17 0.09, 0.30 19 0.169 23.7 0.372
40 2 (0.2) 991 0.13 0.04, 0.45 8 0.197 28.9 0.889
42 3 (0.2) 1,573 0.05 0.02, 0.15 11 0.102 37.2 1.345
44 3 (0.4) 729 0.14 0.03, 0.66 5 0.147 41.1 1.324
45 119 (4.8) 2,464 0.35 0.22, 0.55 23 0.054 34.4 0.358
51 54 (2.7) 1,971 0.10 0.05, 0.20 19 0.014 46.3 0.901
52 96 (4.0) 2,394 0.16 0.11, 0.23 21 0.293 12.7 0.091
53 22 (1.1) 1,981 0.07 0.04, 0.12 16 0.380 6.4 0.075
54 1 (0.1) 1,263 0.06 0.02, 0.16 9 0.580 0.0 0.000
56 22 (1.0) 2,303 0.09 0.05, 0.16 20 0.278 14.2 0.230
58 127 (4.7) 2,685 0.24 0.15, 0.38 22 <0.001 56.8 0.583
59 24 (1.1) 2,218 0.17 0.09, 0.31 16 0.537 0.0 0.000
61 2 (0.2) 1,130 0.05 0.02, 0.14 8 0.739 0.0 0.000
62 1 (0.2) 558 0.07 0.02, 0.23 6 0.420 0.0 0.000
66 16 (0.7) 2,181 0.08 0.05, 0.14 18 0.799 0.0 0.000
67 4 (0.3) 1,342 0.21 0.06, 0.67 10 0.181 28.6 1.020
68 8 (0.5) 1,661 0.07 0.04, 0.14 14 0.439 0.8 0.013
69 9 (1.3) 672 0.28 0.09, 0.92 5 0.249 25.8 0.473
70 6 (0.4) 1,496 0.07 0.03, 0.14 11 0.565 0.0 0.000
71 1 (0.1) 672 0.03 0.01, 0.13 4 0.527 0.0 0.000
73 8 (0.7) 1,151 0.16 0.06, 0.41 10 0.617 0.0 0.000
74 1 (0.4) 264 0.10 0.00, 3.41 2 0.051 73.8 4.874
81 1 (0.1) 1,257 0.04 0.02, 0.10 11 0.966 0.0 0.000
82 4 (0.4) 892 0.13 0.04, 0.36 7 0.939 0.0 0.000
*HPV prevalence among cases, with no distinction between simple and multiple infections, across the studies that reported counts of the HPV genotypes under
consideration. †Number of cases tested for the given HPV genotype. ‡Number of studies included in each meta-analysis. Abbreviations: HPV human papilloma virus, OR
odds ratio, CI confidence interval.
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Sensitivity analyses
When Peto’s method for fixed-effect models was applied
rather than DerSimonian and Laird’s random-effects
models, the first six HPV genotypes ranked in the exact
same order according to their pooled ORs and yielded
similar point estimates with narrower CIs, e.g., 0.65 [0.52,
0.80] for HPV-18 and 0.36 [0.26, 0.49] for HPV-45. More
generally, the top 12 were common to both methods
except for HPV-30 versus HPV-34 (Additional file 4).
Second, using the random-effects model with a lower
CC = 0.25, the first 10 genotypes were the same but
ranked in a different order starting at the fifth. Point
estimates and CIs were virtually unchanged (e.g., 0.63
[0.50, 0.78] for HPV-18 and 0.33 [0.21, 0.53] for HPV-
45). With CC = 0, the discrepancy was much greater:
HPV-18 ranked second (0.62 [0.50, 0.77]) after HPV-40,
which had a very wide CI, and HPV-45 ranked fourth
(0.32 [0.20, 0.52]) after HPV-44. Indeed, fewer studies
were included in this analysis (those with no control or
no case for the HPV genotype considered were ex-
cluded). In particular, the OR associated with HPV-67
(ranked 8 in our main analysis) could not be calculated
but eight genotypes (HPV-18, -33, -34, -39, -45, -58, -59
and -69) among the first 10 were common to the two
methods (Additional file 4).
Finally, considering HPV-negative women as the ref-
erence group yielded very different estimates but a not-
so-different pattern in terms of ranking. First, HPV-16
(which was not assessed in our relative model) had an
OR of 136.7 [70.0, 266.9]. Except for HPV-16, seven of
the first 10 genotypes were common to both methods,
but with scrambled orders. In particular, HPV-67 (89.8
[13.6, 593.6]) and HPV-69 (81.0 [5.0, 1313.3]) ranked
between HPV-18 (99.1 [49.8, 197.2]) and HPV-45 (70.5
[34.3, 144.8]) but their CIs were particularly wide
(Additional file 4).
Figure 2 Pooled odds ratios estimating the oncogenic potential of each HPV genotype relative to HPV-16. NOTE: HPV genotypes were
classified according to the International Agency for Research on Cancer [8,11], as follows: *Carcinogenic (Group 1), †probably carcinogenic
(Group 2A), ‡possibly carcinogenic based on limited evidence in humans (Group 2B), ||possibly carcinogenic based on phylogenetic analogy to
HPV genotypes with sufficient or limited evidence in humans (Group 2B), and §unclassifiable (Group 3). HPV-6, -11, -16, -18, -31, -33, -45, -52
and -58 are putatively included in the future nonavalent anti-HPV vaccine. Precise point estimates and 95% confidence interval limits illustrated
in this figure are available in Table 2, columns 5 and 6.
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Discussion
Conducting meta-analyses of published epidemiologic
studies enabled us to rank 32 HPV genotypes according to
their oncogenic potential relative to HPV-16. All HPV ge-
notypes studied had much smaller estimated oncogenic
potentials than HPV-16, reinforcing its being considered
the “most potent HPV genotype” [8,11]. Following
HPV-16, the HPV genotypes with the highest oncogenic
potentials were, in descending order of their pooled
ORs: HPV-18, -45, -69, -58, -31, -33, -34, -67, -39, -59, -73
and -52.
Globally, it is reassuring that the HPV genotypes
accorded the highest relative oncogenic potentials in our
analyses were indeed IARC-classified as carcinogenic.
Moreover, the genotypes with the highest ORs and rela-
tively narrow CIs, namely HPV-18, -31, -33, -39,-45, -52,
-58 and -59, all belong to the α-7 and α-9 species and
are IARC-classified as carcinogenic to humans with suf-
ficient evidence [8,11]. Pertinently, all these genotypes
except HPV-18 showed largely overlapping CIs, while
HPV-18 (α-7) ranked closest to, but distinct from, HPV-
16 (α-9), supporting its being considered separately
from the other potentially oncogenic genotypes charac-
terized by a risk continuum without a clear break point
(Figure 2).
Surprisingly, HPV-35, -51 and -56, also IARC-classified
as carcinogenic and commonly detected in ICC [57],
ranked lower in our analysis (OR ≤0.15). The same was
observed for HPV-68 (α-7), currently IARC-classified as
probably carcinogenic and among “probably high-risk
genotypes” [10]. So, based on epidemiologic data alone,
our analysis would suggest milder oncogenic potentials
for HPV-35, -51, -56 and -68 than inferred from the IARC
classification, although we acknowledge that more evi-
dence (e.g., mechanistic) needs to be considered [9].
Notably, our results provide insights into the oncogenic
potentials of several genotypes currently IARC-classified
as probably oncogenic in humans. Our meta-analytic
assessment of the oncogenic potentials of HPV-69 and -82
(both α-5 species), -30 (α-6), -67 (α-9), and -34 and -73
(α-11) was based on small numbers of cases, which
yielded particularly wide CIs. However, they ranked
among carcinogenic HPV genotypes, which could sug-
gest stronger oncogenic potentials than assumed so
far. To date, evidence for HPV-30, -34 and -69 has
relied on their phylogenetic analogy to other HPV
genotypes, while HPV-67, -73 and -82 were positively
associated with cancer but lack strong mechanistic evi-
dence [8,11]. In contrast, HPV-53, -66 and -70, also
placed in the probably carcinogenic subgroup [8,11],
had lower relative ORs in our analyses. Hence, overall,
our analysis of available epidemiologic data provided
more discrepant results for the probably carcinogenic
genotype distribution.
Conversely, little to no mechanistic evidence supports
that HPV-6 and -11 (both α-10 species), which commonly
cause benign genital warts, can contribute to carcinogenesis
and they remain unclassifiable as to their carcinogenicity
in humans [8,11]. Our meta-analyses consistently ranked
both at the end of the distribution with estimated pooled
ORs ≤0.15. We should mention that our HPV-16 refer-
ence model did not allow us to disentangle less oncogenic
from non-oncogenic genotypes.
Finally, no epidemiologic evidence suggests cervical
oncogenicity for HPV-40 and -44 [11]. In phylogenetic
terms, these genotypes belong rather to non-oncogenic
species (α-8 and -10, respectively) [58] and have been
considered “low-risk” genotypes [10]. In our main analysis,
these two genotypes ranked before HPV-6 and -11. How-
ever, their estimated ORs were based on limited data and
their classification was not robust in the sensitivity ana-
lyses (Additional file 4). Taken together, our results do not
support HPV-40 and -44 oncogenic potentials.
Strengths of our study derive from methodologic
choices. To date, the assessment of the HPV-genotype–
specific oncogenic potential in cervical cancer has mainly
been based on HPV-genotype–prevalence data among
cases [13,57,59,60]. However, that knowledge alone may
be insufficient to fully appreciate each genotype’s onco-
genic potential. For a given HPV genotype, low frequency
in ICC (corresponding to a small etiologic fraction) could
reflect low prevalence in the general population or low
oncogenic potential. In our study, HPV-genotype ranking
according to their prevalences in cases visibly differed
from that according to their estimated relative oncogenic
potentials. For example, HPV-39 and -59 (both α-7), about
four times less prevalent than HPV-52 (α-9), had higher
oncogenic potentials estimated by their pooled ORs
(Table 2); yet all three genotypes are IARC-classified as
carcinogenic.
To our knowledge, the risks associated with the different
HPV genotypes have rarely been assessed and HPV-
negative, rather than HPV-16–positive, subjects served as
the reference group to calculate ORs [4,10] with at least
one exception [61]. Our similar third sensitivity analysis
found lower OR estimates of the same order of magnitude
as those previously published [10], e.g., respectively, 136.7
versus 281.9 for HPV-16 and 99.1 versus 222.5 for HPV-
18. Notably, that third analysis showed no clear break
point between HPV-18 and the other genotypes, with ORs
decreasing progressively from HPV-16 to the end, unlike
our main analysis. The choice of this reference group may
be questioned because it takes uninfected cases into
account for OR calculation, even though it is currently
accepted that persistent HPV infection is required to cause
ICC [2-4]. With few or no HPV-negative cases of cervical
cancer expected, estimation of ORs and their CIs may
become problematic. Therefore, we chose the unusual
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approach of using HPV-16–infected subjects as the refer-
ence category. HPV-16’s high oncogenic potential is well-
documented [8,11], this genotype is highly prevalent in
cases [13,57] and often identified in women with normal
cytology [62,63]. In our opinion, considering HPV-16–
infected women as the reference group seemed more con-
sistent with the natural history of cervical cancer and
could be more appropriate for estimating HPV-genotype
oncogenic potentials, regardless of their prevalence. How-
ever, the control group’s baseline risk of developing ICC
cannot be considered low, meaning that ORs cannot be
directly interpreted as an accurate estimate of the relative
risk, even though they can be used to rank genotypes.
Alternatively, estimating ORs relative to an established
low-risk genotype, e.g., HPV-6, was limited by the small, if
not inexistent, numbers of ICC cases positive for such a
genotype.
Herein, we combined study ORs using the random-
effects model, as sometimes recommended to perform
meta-analyses of published data [64]. This approach im-
plies wider CIs than in a fixed-effect model because, in
addition to random fluctuations, the random-effects
model allows for variability of the real risk. However, sen-
sitivity analyses showed our results to be consistent with
those obtained using Peto’s method (Additional file 4),
thereby indicating that the wide CIs mostly reflected the
scarcity of epidemiologic data, rather than the choice of
statistical models.
Some authors questioned the use of CC in the random-
effects model, when the underlying risk varies among stud-
ies [65]. Our sensitivity analyses with a halved CC factor
differed only slightly from our main results. In contrast,
applying no CC raised estimation difficulties preventing the
calculation of two pooled ORs (Additional file 4). Never-
theless, our choice is supported by the consistencies, both
external (with the literature) and internal (across other
sensitivity analyses), of our findings after correction.
Our meta-analysis has several limitations that warrant
being mentioned. First, we applied stringent selection
criteria, including only studies with sufficient numbers
of HPV-positive cases and controls. That choice ren-
dered the several large investigations conducted in
North America ineligible [66,67], which is consistent
with 85% of ICC cases occurring in developing coun-
tries [1], and HPV-vaccine trials being conducted more
frequently in Asia-Pacific, Europe or Latin America
than North America [68,69]. Nevertheless, although the
distributions of HPV genotypes vary across populations
[18,57,59,63], no evidence indicates that HPV-type–specific
oncogenic potential could differ according to geographic
area. Moreover, the continent did not explain heterogen-
eity in our meta-analyses.
Second, basing this study on summary data meant we
could not control for age, despite its being a critical
variable, closely associated with HPV infection, clear-
ance, persistence and progression. Age information was
frequently missing and rarely available for HPV-positive
cases and controls specifically. Controls tended to be
10 years younger than cases on average, possibly reflecting
different stages in the natural history of cervical cancer.
The peak prevalence of cervical HPV infection coincides
closely with first-time sexual intercourse, at around
20 years of age, while that of ICC occurs at 40–50 years
[70]. It was reassuring that the comparability of age dis-
tributions between cases and controls did not clearly
explain heterogeneity in our meta-analyses.
Third, the small number of cases infected with some
HPV genotypes hindered precise estimations of their
oncogenic potentials. This paucity is partly due to our
strict definition of cases as having ICC. This choice was
motivated by the natural history of cervical cancer,
according to which precancerous lesions, even high-grade
cervical intraepithelial neoplasia, may regress in a substan-
tial proportion of cases [71]. Previous studies [17,72]
might have been more permissive, assimilating high-grade
lesions and ICC cases, especially longitudinal studies,
often limited by the low numbers of ICC during the
follow-up. Moreover, clinical management guidelines also
recommend the excision of precancerous lesions, and will
continue to do so as long as whether these would regress
or progress cannot be foreseen [73].
Fourth, we did not distinguish between ICC histologic
types, even though HPV-18 could be more prevalent in
adenocarcinomas than squamous cell carcinomas [13].
However, the HPV-genotype–specific distribution according
to histologic type was seldom reported in selected studies.
When histologic type was reported, most were squamous
cell carcinomas, which is the most common histologic
cervical cancer type [74].
Fifth, our analysis was limited by the variety of sample
types and HPV assays, as in previously reported meta-
analyses of HPV-genotype–specific prevalences [57,59,60].
Although all HPV-detection methods were PCR-based,
sensitivity and specificity of PCR protocols varied across
studies and numerous HPV genotypes were not detected
by some of them. However, each study used the same
HPV-typing method for cases and controls, so it is un-
likely that the differences among studies affected our
estimates. Moreover, the heterogeneity in our meta-
analyses was not explained by the HPV-detection
threshold for cases.
Finally, because the components of multiple infections
were seldom available, the oncogenic potential of each
HPV genotype was assessed without distinguishing between
single or coinfection. Thus, the oncogenic potentials of
some HPV genotypes might have been overestimated in
our meta-analysis if they had been coinfection partners with
established high-risk genotypes, e.g., HPV-16 or -18, and
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were wrongly accorded equal weight in cancerous lesions
even though the high-risk genotype was solely responsible
for the lesions [11]. That possibility could explain HPV-
11’s unexpectedly higher oncogenic potential. Moreover,
for studies that did not report coinfection, misattribution
of the causal HPV genotype could bias the estimated
oncogenic potentials of coinfecting HPV genotypes either
way [75]. A new generation of molecular studies involving
lesion microdissection and HPV-E6/E7 expression could
provide valuable information to assess more specifically
each HPV genotype’s oncogenic potential [9,76].
Conclusions
Our results provide further evidence reinforcing the high
oncogenic potentials of genotypes HPV-18, -31, -33, -45, -52
and -58, already classified as high-risk for ICC. They also
highlight the need to include in detection kits HPV-34, -67,
-69 and -73, for which epidemiologic data are currently lack-
ing, and to further examine their possibly underestimated
oncogenic potentials. Moreover, although HPV-39 and -59
belong to the same α-7 species as HPV-18, they are not, at
present, included in a future nonavalent anti-HPV vaccine
(HPV-6, -11, -16, -18, -31, -33, -45, -52 and -58) [77].
Those genotypes may deserve further consideration,
owing to accumulating evidence (relatively precise esti-
mates) and their classification among the 10 most onco-
genic genotypes after HPV-16 in our meta-analyses.
Pooling individual data from presently available and future
studies investigating these genotypes would allow more
robust estimates, especially if controlled for age. Overall,
such findings may have important implications for the
prevention of cervical cancer and could help guide
HPV-based–screening programs [78] and the compos-
ition of the second-generation anti-HPV vaccines [79].
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Additional file 2: Meta-analyses assessing the relative oncogenic
potential of each human papillomavirus (HPV) genotype (forest
plots). Studies are listed in alphabetical order. Each study is represented
by a black cross, which corresponds to the odds ratio (OR) point
estimate; a grey square, whose area reflects the weight each study
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95% confidence interval (CI). The diamond at the bottom of the graph
represents the combined OR and its 95% CI. The solid vertical line is an
oncogenic potential equal to that of HPV-16 (OR 1.0) and the dotted
vertical line indicates the value of the combined ORs from the random-
effects model. The graphs were generated by Stata command metan
(adapted from [26] pp 14 and 33).
Additional file 3: Bias assessment for each meta-analysis (funnel
plots). Each dot represents one study. The solid vertical line is the
pooled odds ratio (OR). Diagonal dashed lines represent the pseudo 95%
confidence limits around the pooled OR for each standard error of the
ordinate vertical axis values, defining a funnel within which 95% of the
studies should lie in the absence of heterogeneity or selection biases.
The yellow line is the fitted linear-regression line of the OR plotted
against its standard error (both on natural logarithm scales) and
corresponds to Egger’s test for funnel-plot asymmetry. The graphs were
generated by the Stata command metafunnel (adapted from [29] pp 113
and 115).
Additional file 4: Sensitivity analyses of human papillomavirus
genotype ranking. *Analyses using a fixed-effect model [27]. †Analyses
using DerSimonian and Laird’s random-effects model [20] with a
continuity correction (CC) = 0.25. ‡Analyses using DerSimonian and
Laird’s random-effects model [20] with CC = 0. HPV-62 and -69 ORs could
not be calculated. §Analyses using DerSimonian and Laird’s random-effects
model [20] (CC = 0.5), with HPV-negative subjects as the reference group. In
this model, unlike the preceding ones, the pooled OR for HPV-16 could be
estimated. Abbreviations: HPV, human papilloma virus; OR, odds ratio; CI,
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